Media

As part of our £1bn R&D investment to get ahead of #infectiousdiseases in lower-income countries we’re working w/@DNDi @dundeeuni to discover shorter, simpler treatments for #VisceralLeishmaniasis. Learn more ⬇️ #AheadTogether twitter.com/GSK/status/154…

We’re at @WLeish7 feeling inspired 💡 by the power of#sciencee to get ahead of#VisceralLeishmaniasiss, a Neglected Tropical Disease, which over 600 million people worldwide are at risk of acquiring.B

#News for #Investors and #Media on @ViiVHC's HPTN study presented at #AIDS2022 More at: gsk.to/3JaybAe

#News for #Investors and #Media on our commitment to voluntary licensing for populations with unmet needs in HIV. More at gsk.to/3voUvk6 #AIDS2022

The correct answer is 900,000 people. Nearly 900,000 people die every year due to #hepatitisB complications. #WorldHepatitisDay #Hepcantwait twitter.com/GSK/status/155…

#News for #investors and #media: We’ve signed agreements with the @EU_Commission, @BARDA, @WHO and @Canada to support pandemic preparedness.

Nearly 900,000 people die every year from complications due to #HepatitisB. At GSK, we are using science, technology and talent to get ahead of hepatitis together. We can’t wait for a world without #hepatitis. #Hepcantwait #WorldHepatitisDay

Today is #WorldHepatitisDay. Let’s test your knowledge! In average, how many people die every year due to #HepatitisB complications?

News for #Investors and #Media See our key numbers from Q2 2022 at a glance. gsk.to/3J8Gz38

Our CEO, Emma, sums up our Q2 results for #Investors and #Media.